期刊
BIOORGANIC & MEDICINAL CHEMISTRY
卷 24, 期 21, 页码 5481-5494出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2016.09.004
关键词
GPCR; GPR40; Free fatty acid receptor 1; FFA1 agonists; Type 2 diabetes mellitus; Prins reaction; Spirocyclic motifs; Metabolic stability
资金
- Russian Scientific Fund [14-50-00069]
- Russian Science Foundation [14-50-00069] Funding Source: Russian Science Foundation
The free fatty acid receptor 1 (FFA1), a G protein-coupled receptor (GPCR) naturally activated by long chain fatty acids is a novel target for the treatment of metabolic diseases. The basic amine spirocyclic periphery of Eli Lilly's drug candidate LY2881835 for treatment of type 2 diabetes mellitus (which reached phase I clinical trials) inspired a series of novel FFA1 agonists. These were designed to incorporate the 3-[4-(benzyloxy)phenyl]propanoic acid pharmacophore core decorated with a range of spirocyclic motifs. The latter were prepared via the Prins cyclization and subsequent modification of the 4-hydroxytetrahydropyran moiety in the Prins product. Here, we synthesize 19 compounds and test for FFA1 activity. Within this pilot set, a nanomolar potency (EC50 = 55 nM) was reached. Four lead compounds (EC50 range 55-410 nM) were characterized for aqueous solubility, metabolic stability, plasma protein binding and Caco-2 permeability. While some instability in the presence of mouse liver microsomes was noted, mouse pharmacokinetic profile of the compound having the best overall ADME properties was evaluated to reveal acceptable bioavailability (F= 10.3%) and plasma levels achieved on oral administration. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据